Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary techno... Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers. Mehr anzeigen
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201...
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – –...
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.22 | -8.49420849421 | 2.59 | 2.59 | 2.2 | 939532 | 2.37920105 | CS |
| 4 | 0.02 | 0.851063829787 | 2.35 | 2.879 | 1.9407 | 1402286 | 2.42904663 | CS |
| 12 | -2.19 | -48.0263157895 | 4.56 | 5.46 | 1.76 | 2723104 | 3.01139402 | CS |
| 26 | -4.59 | -65.9482758621 | 6.96 | 7.27 | 1.76 | 1758540 | 3.53390227 | CS |
| 52 | -18.66 | -88.7303851641 | 21.03 | 26.35 | 1.76 | 1455837 | 7.57350999 | CS |
| 156 | -0.42 | -15.0537634409 | 2.79 | 26.35 | 0.59 | 993619 | 8.02737825 | CS |
| 260 | -14.56 | -86.0011813349 | 16.93 | 26.35 | 0.59 | 663146 | 8.06677603 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 731,1M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,5M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 341,8M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 237,15M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,44M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
